Cybin is trading 10.75% up at $13.70 after announcing four HLP003 poster presentations at Psych Congress 2026.
- Presentations include updates from its Phase 1/2a study and ongoing PARADIGM Phase 3 program.
- Investors are focused on the expected fourth-quarter Phase 3 readout for HLP003, which has Breakthrough Therapy designation.
- Major indexes are up more than 0.5%, providing additional support in the broader risk-on market.